Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

• Status: Terminated
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• 18 years of age or older

• Body weight >/= 99lbs

• ECOG 0-2

• Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy

• Screening hemoglobin level of Exclusion Criteria:

• History of or concurrent second malignancy

• Evidence of primary or metastatic malignancy involving the Central Nervous System